Aetna Inc., a national health insurer incorporated in Pennsylvania, has agreed to pay $117.7 million to resolve allegations that it violated the False Claims Act by submitting — or failing to correct — inaccurate diagnosis codes for patients enrolled in its Medicare Advantage plans. According to federal investigators, those inaccurate codes resulted in inflated payments from Medicare.
On its face, the settlement reads like another corporate compliance case. A large insurer, a large payout, a set of allegations resolved without an admission of wrongdoing. But beneath the legal language sits a far more uncomfortable question about the structure of the American healthcare system itself: what happens when private corporations are paid billions of taxpayer dollars to care for the nation’s elderly, while simultaneously being rewarded by investors for maximizing revenue and reducing costs?
The Aetna case offers a window into that tension.
Medicare Advantage, also known as Medicare Part C, allows seniors to enroll in private insurance plans instead of traditional government-run Medicare. These plans are run by private insurers known as Medicare Advantage Organizations.
Under the program, the Centers for Medicare and Medicaid Services pays insurers a fixed monthly amount for each enrollee. That payment increases depending on how sick a patient is expected to be. The more serious the diagnoses attached to a patient’s file, the higher the payment the insurer receives.
To calculate those payments, insurers submit diagnosis codes to the government documenting the medical conditions of their patients.
Federal officials say Aetna submitted inaccurate or unsupported diagnosis codes that increased those payments. Investigators also say the company failed to withdraw certain codes after they were found to be unsupported and falsely certified that the data submitted to regulators was accurate.
The settlement resolves those allegations.
“The government pays private insurers over $530 billion each year to care for Americans enrolled in Medicare Advantage,” said Assistant Attorney General Brett A. Shumate of the Justice Department’s Civil Division. “We will continue to hold accountable insurers that knowingly submit inaccurate or unsupported diagnoses to improperly inflate reimbursement.”
Investigators say part of the issue traces back to a chart review program Aetna used in 2015. The program paid coders to review patient records and identify conditions supported by medical documentation.
According to federal officials, Aetna used those reviews to add new diagnosis codes, thereby increasing the payments it received from Medicare.
But when those same reviews suggested that previously submitted diagnoses were unsupported, investigators say the company did not remove them — a step that would have required the insurer to repay the government.
In effect, prosecutors argue the program allowed the company to identify opportunities for additional payments while ignoring evidence that it may have already been overpaid.
The settlement also resolves allegations spanning 2018 through 2023 involving diagnosis codes related to morbid obesity.
Morbid obesity diagnoses are typically supported by Body Mass Index measurements documented in patient records. Federal investigators say some of the codes submitted by Aetna were inconsistent with BMI data in those records, resulting in increased Medicare payments.
Part of the case arose from a lawsuit filed by a former Aetna risk-adjustment coding auditor under the False Claims Act’s whistleblower provisions. Those provisions allow private individuals to sue on behalf of the government when they believe fraudulent claims have been submitted for federal funds.
The whistleblower in the case, Mary Melette Thomas, will receive $2,012,500 as part of the settlement.
While the agreement resolves these allegations, Aetna’s legal history reflects a broader pattern that has followed the private insurance industry for decades.
The company, now owned by CVS Health following a massive merger in 2018, has previously faced lawsuits and investigations related to physician reimbursement, billing practices, and claim denials. In the early 2000s, Aetna paid hundreds of millions of dollars to settle class-action lawsuits brought by doctors who accused the insurer of systematically underpaying medical providers.
Patient advocates have also raised concerns about the growing use of automated claim review systems and complex billing processes that can result in delayed or denied care.
For many Americans, those disputes are not abstract policy debates. They are decisions that can shape whether a patient receives treatment.
One of the most widely cited cases involved Nataline Sarkisyan, a 17-year-old leukemia patient in California whose doctors recommended an emergency liver transplant in 2007. Her insurer initially denied coverage for the procedure, calling it experimental. After intense public protests and national media attention, the company reversed its decision. Sarkisyan died hours later before the transplant could take place.
Stories like that have helped fuel a growing frustration among patients navigating the American healthcare system.
Even when people have insurance, the path to receiving care can involve prior authorization requirements, coverage disputes, and complex billing rules that many patients struggle to understand.
At the same time, healthcare costs continue to climb.
In 2024, healthcare spending in the United States reached approximately $5.3 trillion, accounting for roughly 18 percent of the country’s entire economy.
Insurance premiums have also surged. The average annual premium for family coverage reached nearly $27,000 in 2025, with workers paying thousands of dollars of that cost themselves.
Since 2015, family premiums have increased by more than 50 percent.
Prescription drugs add another layer of pressure. Americans spend more than $600 billion each year on medications, and surveys show nearly one in four patients struggles to afford their prescriptions.
Yet the challenges facing the system extend beyond cost alone.
Across the country, hospitals are grappling with staffing shortages, rising operating costs, and the financial strain of caring for aging populations. In rural communities, dozens of hospitals have closed or scaled back services in recent years, leaving many patients with fewer options for care.
Meanwhile, Medicare Advantage itself has become a financial powerhouse on Wall Street.
Today, more than half of all Medicare beneficiaries are enrolled in Medicare Advantage plans, and the program represents one of the most profitable segments of the private insurance industry. Investors closely watch enrollment growth, reimbursement rates, and risk-adjustment payments because they directly influence the revenues of companies like UnitedHealth, Humana, and CVS Health.
That dynamic creates a difficult reality at the heart of the system: the same program designed to care for aging Americans has also become a major revenue stream for publicly traded corporations whose primary legal obligation is to deliver returns for shareholders.
Cases like the Aetna settlement sit at the intersection of those two realities.
Supporters of private insurance argue that companies help control costs and coordinate care within a complex healthcare system.
Critics say the incentives embedded in that system encourage insurers to push diagnoses upward when billing the government while pushing payments downward when covering patient care.
The result, for many Americans, is a system that often feels impossible to navigate.
Coverage may exist on paper. But access to timely, affordable care can still depend on whether a treatment is approved, whether a provider is in network, or whether a claim is denied.
The Aetna settlement will return more than $117 million to the federal government. But the deeper issue it exposes is not simply about one insurer or one case.
It is about a healthcare system that now consumes nearly one-fifth of the American economy while leaving millions of patients struggling to afford care, find doctors, or understand the rules governing their own insurance.
When a comment was requested from Aetna, they responded with:
“Aetna continues to disagree with the DOJ’s industry-wide allegations, and this settlement should not be seen as an acknowledgment of liability. Instead, we are now able to avoid the uncertainty and further expense of prolonged litigation, as we maintain our focus on delivering first-in-class member experience across our Medicare Advantage plans.” Phillip Blando, Aetna Spokesperson.
In 2025, Aetna generated $2.9 billion dollars of profit.
At some point, the question stops being whether one company misreported diagnosis codes.
The real question becomes whether the structure of the system itself is working — or whether the country has built a healthcare economy so financially complex that accountability arrives only after billions have already been spent.
For millions of Americans trying to navigate illness, insurance, and rising costs, that question is no longer theoretical.
It is urgent.
